- Home
- CGEM vs DEA Comparison
CGEM vs DEA Comparison
Compare CGEM & DEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGEM | DEA |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CGEM | DEA |
|---|---|---|
| Price | $17.60 | $25.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 5 |
| Target Price | ★ $30.13 | $23.49 |
| AVG Volume (30 Days) | ★ 1.1M | 447.3K |
| Earning Date | 05-11-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 7.77% |
| EPS Growth | N/A | ★ 50.00 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $336,099,000.00 |
| Revenue This Year | N/A | $5.41 |
| Revenue Next Year | $5.20 | $3.33 |
| P/E Ratio | ★ N/A | $1,284.50 |
| Revenue Growth | N/A | ★ 11.27 |
| 52 Week Low | $5.68 | $20.56 |
| 52 Week High | $19.43 | $25.79 |
Technical Indicators
Market Signals| Indicator | CGEM | DEA |
|---|---|---|
| Relative Strength Index (RSI) | 55.99 | 62.19 |
| Support Level | $17.19 | $20.89 |
| Resistance Level | $19.10 | $25.67 |
| Average True Range (ATR) | 0.99 | 0.50 |
| MACD | -0.18 | 0.02 |
| Stochastic Oscillator | 60.63 | 67.09 |
Price Performance
Historical ComparisonAbout CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
About DEA Easterly Government Properties Inc.
Easterly Government Properties Inc is a real estate investment trust. The company is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. It generates all its revenue by leasing its properties to such agencies. The company operates in single segment for the purposes of assessing performance and making operating decisions.